data-integrity

NEJM Retracted the Study That Approved Amgen's Vasculitis Drug. It Had Never Done That in 200 Years.

The FDA says the drug's superiority result came from re-scoring nine patients after the trial was unblinded. It is still on U.S. shelves while Amgen fights the withdrawal.